LFST insider Form 4 shows 57,240-share sale, 261,292 shares remain

Rhea-AI Filing Summary

LifeStance Health Group, Inc. (LFST) disclosed that an executive sold company stock. On 11/21/2025, the Executive Vice President, Practice Operations reported selling 57,240 shares of LifeStance common stock at a weighted average price of $6.43 per share, in multiple trades between $6.41 and $6.50. After these sales, the executive beneficially owns 261,292 shares of LifeStance common stock. The filing notes that full trade details for each price within the range are available upon request.

Insider Trade Summary

Net Seller: 57,240 shares

Net Sell 1 txn

Insider Miller Lisa K

Role See Remarks

Sold 57,240 shs ($368K)

Type	Security	Shares	Price	Value
Sale	Common Stock	57,240	$6.43	$368K

Holdings After Transaction: Common Stock — 261,292 shares (Direct)

Footnotes (1)

1. F1. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $6.41 to $6.50 inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/25/2025 - 04:25 PM Learn about SEC filing dates

FAQ

What insider transaction did LifeStance Health Group (LFST) report?

LifeStance Health Group reported that an executive sold 57,240 shares of its common stock on 11/21/2025.

At what price were the LFST shares sold in this Form 4 filing?

The shares were sold at a weighted average price of $6.43 per share, in multiple trades ranging from $6.41 to $6.50.

How many LifeStance (LFST) shares does the reporting person still own?

Following the reported sale, the executive beneficially owns 261,292 shares of LifeStance common stock.

Who is the insider involved in this LifeStance Health Group Form 4?

The reporting person is an officer of LifeStance, serving as Executive Vice President, Practice Operations.

Does this LFST Form 4 involve derivative securities or only common stock?

The reported transaction in this filing involves common stock; the derivative securities table shows no reported derivative transactions.

Was the LifeStance (LFST) insider sale executed in multiple trades?

Yes. The filing states the price is a weighted average and that the shares were sold in multiple transactions between $6.41 and $6.50.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Lisa K

(Last) (First) (Middle)

C/O LIFESTANCE HEALTH GROUP, INC.

4800 N. SCOTTSDALE ROAD, SUITE 2500

(Street)

SCOTTSDALE AZ 85251

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeStance Health Group, Inc. [ LFST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/21/2025		S		57,240	D	$6.43(1)	261,292	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $6.41 to $6.50 inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

Executive Vice President, Practice Operations

	By: /s/ Ryan Pardo, Attorney-in-Fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.